Literature DB >> 2963998

Long-term oral ciprofloxacin for infection prophylaxis in allogeneic bone marrow transplantation.

T de Witte1, I Novakova, J Branolte, H Muytjens, B de Pauw.   

Abstract

The efficacy of oral ciprofloxacin to prevent bacterial infections during the first three months after allogeneic bone marrow transplantation (BMT) was assessed prospectively. Twenty-three recipients of lymphocyte depleted marrow grafts received ciprofloxacin orally, 500 mg twice daily for 90 days after BMT. Nine patients had no infections during ciprofloxacin prophylaxis; in the remaining 14 patients 19 febrile episodes occurred. No infections could be attributed to Gram-negative rods nor to fungal micro-organisms on the basis of the micro-organisms isolated. One infection, a pneumonia due to Bacteroides melaninogenicus, proved to be fatal. Allergic skin reactions were observed in three patients, but neither hematological nor nephrological side-effects could be substantiated in patients who were treated concomitantly with cyclosporine. Prolonged administration of ciprofloxacin turned out to be safe and effective in preventing serious aerobic bacterial infections during the first three months after BMT.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2963998     DOI: 10.1007/bf02075260

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  8 in total

1.  Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.

Authors:  W Brumfitt; I Franklin; D Grady; J M Hamilton-Miller; A Iliffe
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

2.  Bone marrow repopulation capacity after transplantation of lymphocyte-depleted allogeneic bone marrow using counterflow centrifugation.

Authors:  T de Witte; R Raymakers; A Plas; E Koekman; H Wessels; C Haanen
Journal:  Transplantation       Date:  1984-02       Impact factor: 4.939

Review 3.  Infectious complications of bone marrow transplantation.

Authors:  D J Winston; W G Ho; R E Champlin; R P Gale
Journal:  Exp Hematol       Date:  1984-03       Impact factor: 3.084

4.  Nephrotoxicity of trimethoprim and cotrimoxazole in renal allograft recipients treated with cyclosporine.

Authors:  J F Thompson; D H Chalmers; A G Hunnisett; R F Wood; P J Morris
Journal:  Transplantation       Date:  1983-08       Impact factor: 4.939

5.  Colonization resistance of the digestive tract: clinical consequences and implications.

Authors:  D van der Waaij
Journal:  J Antimicrob Chemother       Date:  1982-10       Impact factor: 5.790

6.  Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients.

Authors:  D J Winston; W G Ho; S L Nakao; R P Gale; R E Champlin
Journal:  Am J Med       Date:  1986-05       Impact factor: 4.965

7.  Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia.

Authors:  J Cohen; J P Donnelly; A M Worsley; D Catovsky; J M Goldman; D A Galton
Journal:  Lancet       Date:  1983 Dec 24-31       Impact factor: 79.321

8.  Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

Authors:  H L Muytjens; J van der Ros-van de Repe; G van Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

  8 in total
  2 in total

Review 1.  Use of quinolones in the immunocompromised host.

Authors:  A G Maiche
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 2.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.